{"id":"NCT03406156","sponsor":"AbbVie","briefTitle":"A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy","officialTitle":"A Phase 3b Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-08-10","primaryCompletion":"2021-10-12","completion":"2023-07-12","firstPosted":"2018-01-23","resultsPosted":"2022-11-03","lastUpdate":"2024-08-06"},"enrollment":120,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Lymphocytic Leukemia (CLL)","Small Lymphocytic Lymphoma (SLL)"],"interventions":[{"type":"DRUG","name":"Obinutuzumab","otherNames":["Gazyva"]},{"type":"DRUG","name":"Bendamustine","otherNames":["Bendeka"]},{"type":"DRUG","name":"Venetoclax","otherNames":["Venclexta","ABT-199","GDC-0199"]}],"arms":[{"label":"Obinutuzumab","type":"EXPERIMENTAL"},{"label":"Obinutuzumab/bendamustine","type":"EXPERIMENTAL"}],"summary":"This is a multi-cohort, open-label study in previously untreated participants with chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), excluding those with the 17p deletion, to evaluate a debulking strategy that would enable all participants to receive subsequent venetoclax as outpatients, with lower risk of tumor lysis syndrome.","primaryOutcome":{"measure":"Percentage of Participants Achieving Low Tumor Burden Status With Induction of Obinutuzumab or Obinutuzumab Plus Bendamustine (Debulking Period)","timeFrame":"From Baseline to the end of Cycles 2, 4, and 6, up to approximately 24 weeks after initial dose of study drug","effectByArm":[{"arm":"Obinutuzumab","deltaMin":81.4,"sd":null},{"arm":"Obinutuzumab/Bendamustine","deltaMin":83.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":15,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://www.rxabbvie.com/"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":84},"commonTop":["NAUSEA","INFUSION RELATED REACTION","DIARRHOEA","FATIGUE","NEUTROPENIA"]}}